Impact of RNA degradation on gene expression profiling by Opitz, Lennart et al.
RESEARCH ARTICLE Open Access














Background: Gene expression profiling is a highly sensitive technique which is used for profiling tumor samples
for medical prognosis. RNA quality and degradation influence the analysis results of gene expression profiles. The
impact of this influence on the profiles and its medical impact is not fully understood. As patient samples are very
valuable for clinical studies, it is necessary to establish criteria for the RNA quality to be able to use these samples
in later analysis.
Methods: To investigate the effects of RNA integrity on gene expression profiling, whole genome expression
arrays were used. We used tumor biopsies from patients diagnosed with locally advanced rectal cancer. To
simulate degradation, the isolated total RNA of all patients was subjected to heat-induced degradation in a time-
dependent manner. Expression profiling was then performed and data were analyzed bioinformatically to assess
the differences.
Results: The differences introduced by RNA degradation were largely outweighed by the biological differences
between the patients. Only a relatively small number of probes (275 out of 41,000) show a significant effect due to
degradation. The genes that show the strongest effect due to RNA degradation were, especially, those with short
mRNAs and probe positions near the 5′ end.
Conclusions: Degraded RNA from tumor samples (RIN > 5) can still be used to perform gene expression analysis.
A much higher biological variance between patients is observed compared to the effect that is imposed by
degradation of RNA. Nevertheless there are genes, very short ones and those with the probe binding side close to
the 5′ end that should be excluded from gene expression analysis when working with degraded RNA. These
results are limited to the Agilent 44 k microarray platform and should be carefully interpreted when transferring to
other settings.
Background
High-throughput microarray technology is ideally suited
for analyzing thousands of genes in a single experiment
and allows a better understanding of the molecular
mechanisms of cancer development and progression.
Gene expression arrays have a profound influence on the
development of new diagnostic and therapeutic strate-
gies, such as the prediction of prognosis in breast cancer
[1] or the response to a preoperative radio-chemotherapy
(RT/CT) in rectal cancer [2]. High-quality RNA is
considered a prerequisite for high-throughput analysis.
Nevertheless, RNA degradation is a critical problem in all
experimental settings and for clinical samples in particu-
lar. Additionally, the investigation of clinical samples
poses a second problem. Due to the heterogeneity of
tumor samples, a high number of patients is needed for
statistical analysis. There is thus an ongoing debate as to
how far gene expression results are affected by various
degrees of degradation [3-6] and to what extent of degra-
dation the tissue samples with poor RNA quality can be
included in an analysis.
Degradation of RNA itself is a physiological process
during the cell cycle to regulate RNA-dependent
mechanisms. Many intracellular enzymes, such as ribo-
nucleases, (endo- and exonucleases), as well as other
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any medium, provided the original work is properly cited.cofactors, are involved and exhibit prevalent activity in
all organisms of life [7]. The multiplicity of functions
that characterize ribonucleases in eukaryotes underlines
the key importance of mechanisms that specifically not
only target and degrade RNAs but also function in
RNA-processing reactions and presumably enhance the
overall efficiency of degradation pathways [8,9].
Although these processes were well investigated in the
past and the level of knowledge is increasing steadily, lit-
tle is known as to how far the mechanisms can be trans-
lated into cells that have been taken out of the organism
as is done when biopsies are taken.
Moreover, beside RNA-degrading enzymes and cofac-
tors, tissue-specific factors such as the extent of necrosis
and storage conditions have to be considered to avoid
degradation of RNA. In the past, liquid nitrogen was
considered to be the standard method for archiving tis-
sue samples. This, however, poses numerous logistical
problems surrounding the provision of nitrogen and the
transportation of frozen tissue samples. This is essen-
tially a problem for clinical trials, in which patients are
frequently recruited in non-university hospitals where
access to liquid nitrogen cannot be guaranteed. There-
fore, preserving liquids have been developed and studied
with respect to RNA stability [10-12].
To assess RNA quality, different methods have been
applied [5,13]. The electrophoretic-based generation of a
RNA integrity number (RIN) [14] using Agilent’s Bioana-
lyzer provides a user-independent method of reproduci-
bly assessing degradation of RNA. In the recently
published literature comparing different levels of RNA
integrity, the RIN has frequently been used, thus allowing
easy comparison of the postulated values that were indi-
cated as thresholds for considering good and poor RNA
quality [4,5]. Within these publications, tissue was treated
with different temperature levels to achieve degradation.
Interestingly, the influence of similar temperature levels
resulted in very different degradation results. Further-
more this pre-isolation degradation more or less mimics
a prolonged time to storage and initiates the complex
process of cell hypoxia and consecutive cell death.
Here in this study, we aim to assess the influence of
RNA degradation on gene expression and to analyze the
systematic effect that is observable when using RNA with
different RINs. Therefore, we performed gene expression
analysis of tissues from tumor biopsies of several patients
using gene expression microarrays. We performed degra-
dation by heat-treatment of isolated RNA to avoid tran-
scriptional processes in the context of cell death.
Methods
Samples and sample preparation
Tumor biopsies from three patients with locally advanced
rectal cancer were taken prior to the preoperative radio-
chemotherapy. These patients were treated within the
CAO/ARO/AIO-04 trial (EudraCT-Number: 2006-
002385-20), biopsies were taken according to the guide-
lines set by the Local Ethical Review Board (application
number: 9/8/08) and patients gave written consent. Due to
the rigid rectoscopy, biopsies were stored in RNAlater
(Qiagen, Hilden, Germany) within 10 to 20 seconds after
removal and subsequently kept at 5°C for 24 hours fol-
lowed by storage at -20°C. Extraction of nucleic acids was
carried out four months prior to the following experi-
ments and was performed using TRIZOL (Invitrogen,
Carlsbad, CA) following standard procedures as previously
described [15] (details can be found at http://www.riedlab.
nci.nih.gov/protocols.asp) and stored at -80°C.
RNA Degradation and Quality Control
Heat-induced degradation was carried out at 60°C on a
thermal block (Eppendorf Thermomixer). For each of
the three patients, four different time points were
defined for the analysis of degradation state, namely
0:00 h; 1:45 h; 2:30 h; and 3:15 h respectively. Time
points and degradation temperature were chosen based
on preliminary test results (data not shown) revealing
that no and very low degradation occurred at room tem-
perature and 45°C, respectively.
After thermal degradation, total RNA was checked for
quantity, purity and integrity of the 18 S and 28 S ribo-
somal bands by capillary electrophoresis. RNA degrada-
tion was assessed using the Agilent 2100 Bioanalyzer
following the manufacturer’s standard protocol. In brief,
after loading RNA Nano LabChip with the gel-dye-mix,
each of the 12 measuring chambers was filled with RNA
(concentration between 200-300 ng/μl) and the provided
marker. The measurement was then carried out by the
Bioanalyzer and a separate RNA integrity number as
well as the correlating electropherogram and a gel-like
image was provided by the software for each of the sam-
ples. Each RNA sample was split between four different
tubes. RNA quality was rated according to the RNA
integrity number (RIN). Measurement of RIN was car-
ried out prior to the array hybridization without freezing
and thawing again.
Microarrays
Microarrays were done using the “Low RNA Input lin-
ear Amplification Kit Plus, One Color” protocol (Agilent
Technologies, Inc. 2007; Cat. N°: 5188-5339) and the
Agilent RNA Spike-In Kit for One color (Agilent Tech-
nologies, Inc. 2007; Cat. N°: 5188-5282) following the
manufacturer’s standard protocol. Global gene expres-
sion analysis was applied using the Human 4 × 44 K
design array from Agilent Technologies (G4112F). 600
ng of total RNA were used as a starting material to pre-
pare cDNA. cDNA synthesis and in vitro transcription
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recommendation. Quantity and efficiency of the labeled
amplified cRNA were determined using the NanoDrop
ND-1000 UV-VIS Spectrophotometer version 3.2.1. The
hybridizations were performed for 17 hours at 10 rpm
and 65°C in the Hybridization Oven (Agilent). Washing
and staining of the arrays were done according to the
manufacturer’s recommendation. Cy3 intensities were
detected by one-color scanning using an Agilent DNA
microarray scanner (G2505B) at 5 micron resolution.
Scanned image files were visually inspected for artifacts
and then analyzed.
Semi-quantitative Real-time PCR
One μg of total RNA was reverse-transcribed in a 25 μl
reaction volume into first-strand cDNA using Super-
script III and random hexamers (Invitrogen). Three μl
of cDNA mix was added to 12.5 μlo fi Q™SY BR® Green
Supermix (Bio-Rad Laboratories, Hercules, CA), and 375
ng primer solution to a total of 25 μl per reaction.
Amplification efficiency was assessed using LinRegPCR
[16]. The corresponding primer sequences can be found
in Table 1. Real-time PCR analysis was performed in a
Bio-Rad iCycler iQ5 (Bio-Rad, Munich, Germany) using
the following cycling parameters: 10 min at 95°C, 40
cycles of 15 sec at 95°C, one min at 60°C. The resulting
Ct values were normalized based on the mean of three
housekeeping genes, GAPDH, HPRT1 and YWHAZ.
Data Analysis
Intensity data were extracted using Agilent’s Feature
Extraction (FE) software (version 9.5.3.1) including a
quality control based on internal controls using Agilent’s
protocol GE1_107_Sep09. All chips passed the quality
control and were analyzed using the Limma package
[17] of Bioconductor [18].
The data discussed in this paper are generated in
compliance with the MIAME guidelines and have been
deposited in NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number
GSE17753 http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE17753.
The microarray data analysis consists of the following
steps:
1. between-array normalization, 2. global clustering
and PCA-analysis, 3. fitting the data to a linear model,
4. detection of differential gene expression and 5. over-
representation analysis of differentially expressed genes.
Quantile-normalization was applied to the log2-trans-
formed intensity values as a method for between-array
normalization, to ensure that the intensities had similar
distributions across arrays [19].
For cluster analysis, we used a hierarchical approach
with the average linkage-method. Distances were
measured as 1 - Pearson’s Correlation Coefficient. The
PCA was performed using the princomp-function in the
R software. To estimate the average group values for
each gene and assess differential gene expression, a sim-
ple linear model was fitted to the data, and group-value
averages and standard deviations for each gene were
obtained. To find genes with significant expression
changes between groups, empirical Bayes statistics were
applied to the data by moderating the standard errors of
the estimated values [17].
P-values were obtained from the moderated t-statistic
and corrected for multiple testing with the Benjamini-
Hochberg method [20]. The p-value adjustment guar-
antees a smaller number of false positive findings by
controlling the false discovery rate (fdr). For each gene,
the null hypothesis, that there is no differential expres-
sion between degradation levels, was rejected when its
fdr was lower than 0.05. To find over-represented
functions (as represented by Gene Ontology terms
[21]), we used the additional R package topGO [22].
The statistical significance of comparisons between dif-
ferent gene lists was examined with the nonparametric
Wilcoxon rank sum test, using R. Bonferroni-corrected
[23] p-values < 0.05 were considered significantly
different.
Table 1 PCR Primers used for semi-quantitative real time
PCR validation.
Systematic Name Gene Name Primer Sequence (5’!3’)
NM_005185.2 CALML3 Fwd: AGGCCTTCTCCCTGTTTGAC
Rev: CCGGTCGATCTCACTCATC
NM_018403.4 DCP1A Fwd: AGCATCACCAGCAGATCCTT
Rev: TATTCCACAGCCTTGCTCCT
NM_145301.2 FAM18B2 Fwd: AAGAGCCATTGGGTGTTTGA
Rev: AGGCAATAAGTCCCAACCAA
NM_005336.3 HDLBP Fwd: CAGGACCTGCTCCACTGTTT
Rev: AGGCCAGAGTGCTGACTGAC
XR_038543.2 LOC644604 Fwd: TGCCTGGGTCTTGGATAAAC
Rev: GGGCATCAACGATAGTCACA
NM_018222.3 PARVA Fwd: TTTGAGCTCATGCAAGATGG
Rev: CGGTACTTGGTGAAGAGGTTG
NM_001135771.1 RPN2 Fwd: GCTTCTGCTCTTCGCTCTGT
Rev: CCAGCATAGCAGCATGTCC
NM_003133.5 SRP9 Fwd: CAGACCTGGGAGGAGTTCAG
Rev: CACAAGTTCCCATCAGAATGC
NM_006082.2 TUBA1B Fwd: ACGTGGTTCCCAAAGATGTC
Rev: CACAGTGGGAGGCTGGTAGT
NM_002046.3 GAPDH Fwd: CCACATCGCTCAGACACCAT
Rev: CCAGGCGCCCAATACG
NM_000194.1 HPRT1 Fwd: TGACACTGGCAAAACAATGCA
Rev: GGTCCTTTTCACCAGCAAGCT
NM_003406.2 YWHAZ Fwd: ACTTTTGGTACATTGTGGCTTCAA
Rev: CCGCCAGGACAAACCAGTAT
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from patient samples, we used Kendall’s rank correlation
coefficient τ.
Results
Effect of RNA degradation on comparability between
patients
In order to analyze the effects of RNA degradation on
gene expression profiles, we selected biopsies of real
patient tissue. Specifically, pre-therapeutic biopsy tumor
samples from three individual patients diagnosed with
rectal cancer were used. The total RNA of each patient
was degraded thermically in a time-dependent manner
(see Methods). Four different time-points of degradation
(Control: 0:00 h, TP1: 1:45 h, TP2: 2:30 h and TP3: 3:15
h) were selected.
To determine the integrity of the RNA starting mate-
rials for the microarray analysis at the different time-
points, we evaluated the quality of each sample using
the RNA integrity number (RIN). Using this tool, sam-
ple integrity is determined by the entire electrophoretic
trace (Bioanalyzer profiles) of the RNA sample, includ-
ing the presence or absence of degradation products.
The Bioanalyzer profiles, as well as the calculated RINs
o ft h es a m p l e s ,a r es h o w ni nF i g u r e1 A .T h ec a l c u l a t e d
RNA integrity numbers for all samples depending on
degradation time are displayed in Figure 1B. A strong
negative correlation between RIN-values and degrada-
tion time in all three patients is evident. The Null-
Hypothesis that there is no negative correlation can be
rejected using a statistical correlation test on Kendall’s
rank correlation (τ = -0:862, p-value = 2.530e-05).
Next, we analyzed the samples of the different patients
at different RNA degradation levels using gene expres-
sion profiling. With this we address the question of how
significant the influence of RNA degradation is on the
gene expression profiles in comparison to the overall
influence of different patients. To gain insights into the
data obtained by the microarrays and, especially, to ana-
lyze how patient samples correlate with degradation
stages, different bioinformatic methods were applied.
The multivariate data analysis method PCA (principal
components analysis) was used to visualize similarities
or dissimilarities between genome-wide expression pro-
files of patient samples and degradation stages in a two-
dimensional plot. PCA is a linear projection method
that allows visualization of high-dimensional data in a
lower dimensional space. The results of the PCA analy-
sis for the normalized microarray dataset are shown in
Figure 2A. The first axis of the plot (first principal com-
ponent, PC1) accounts for 33% of the overall variance of
the data, while the second axis accounts for 29% (PC2).
It can clearly be seen that samples from the same
patient are very similar to each other regardless of the
degradation level. The differences between the different
patients, which are to be analyzed, contribute the major
part of the overall differences.
Furthermore, we applied a clustering approach using
an agglomerative hierarchical clustering algorithm.
Based on the hierarchical clustering, we observe that the
samples which are derived from the same patient cluster
together regardless of the degradation level. To demon-
strate this, the pairwise similarity metrics between sam-
ples was calculated based on normalized expression
measurements of all genes using Pearson’s correlation
coefficient. The hierarchical clustering was applied to
the resulting matrix of pairwise correlation coefficients.
The resulting correlation matrix is shown as a heatmap
in Figure 2B. Similarly to the PCA-results, the correla-
tions between samples of the same patient are much
higher than the correlations between samples of differ-
ent biological backgrounds.
In conclusion, both analysis methods, i.e. cluster ana-
lysis and PCA, provide strong evidence that differences
between patients are larger and more significant than
those observed by the thermal degradation of RNA and
therefore comparison of reliable clinically relevant data
of patient samples will not be hindered by the effects of
RNA degradation for a realistic range of RIN values.
Genes effected by RNA degradation
While the differences we observe between patients out-
weigh the differences we observe due to RNA degrada-
tion, we still wanted to analyze the genes which are
affected by RNA degradation more closely. These are
genes that will have to be carefully considered in studies
where different patient groups are compared, because
their expression might be influenced by the RNA quality
rather than reflecting biological differences between the
patient groups which are to be analyzed.
Analysis of differential gene expression was performed
in order to identify those genes which are significantly
affected by RNA degradation. The quantitative changes
in gene expression with increasing RNA degradation
levels were investigated and the change of expression
level was further considered as level of representation,
i.e. either over- or under-represented RNA species.
For the statistical analysis of differential expression, we
defined four different groups of degradation (Control,
TP1, TP2 and TP3) including three biological replicates
(P159, P160 and P162) per group. Three comparisons
were performed, namely TP1 against the control group
(TP1 vs Control); TP2 against the control group (TP2 vs
Control) and TP3 against the control group (TP3 vs
Control). We considered all differentially expressed
genes (DEGs) with a fdr of 5% and a fold change greater
than 2-fold as significantly altered. The number of sig-
nificant DEGs increases from 15 (TP1 vs Control),
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Page 4 of 14Figure 1 Degradation of RNA. The effect of degradation time on calculated RNA Integrity Numbers (RINs) for the given samples P159, P160
and P162 is shown. (A) Bioanalyzer profiles of total RNA for degradation levels used in the microarray study (control, 1:45 h, 2:30 h, 3:15 h). RINs
are shown next to each total RNA profile. (B) RIN-dependence of degradation time separately for all patients. An additional time point (240 Min/
4:00 h) without gene expression profile is also present.
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Page 5 of 14Figure 2 Effect of RNA degradation on comparability between patients.( A) Two-dimensional PCA plot of genome-wide expression profiles
showing principal components 1 and 2. The first axis (PC1) accounts for 33% of the overall variance of the data, the second axis accounts for
29% (PC2). The colors blue (P159), red (P160) and green (P162) refer to the different patients. The degradation levels are represented by the
following symbols: C (0:00 h), 1 (1:45 h), 2 (2:30 h) and 3 (3:15 h). (B) shows pairwise correlations between all samples of patients. The cells in the
visualization are colored by Pearson’s correlation coefficient values with deeper colors indicating higher positive (blue) correlations. The heatmap
is flanked by clustering dendrograms showing the similarity between samples in a hierarchical approach.
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Page 6 of 1473 (TP2 vs Control) to 275(TP3 vs Control) and is nega-
tively correlated to the RIN values of the corresponding
samples. Furthermore, we analyzed three groups of
RNAs separately in each of the three comparisons: 1.
under-represented as compared to the average RNA
population; 2. over-represented or more-stable to the
rest of the RNA and 3. normally-represented are the
seemingly not-differential genes that are degraded at a
similar level as the average RNA population. We also
noted that the absolute signal intensity of the majority
of genes before normalization decreases with increased
time. Therefore these genes have to be considered as
affected by degradation as well, however, this difference
does not affect analysis due to normalization. The
majority of DEGs is under-represented with the increas-
ing RNA degradation of the samples as can be seen in
Table 2.
To establish a relationship between regulation of
genes and increased thermal degradation, a Venn dia-
gram, shown in Figure 3A, summarizes all comparisons.
The Venn diagram shows that, with one exception, all
candidates between TP1 vs Control and TP2 vs Control
are included in the significant DEGs of TP3 vs Control.
The number of differentially expressed genes increases
with progressive RNA degradation. Given this subset
relation, we performed all further analyses with signifi-
cant DEGs from TP3 vs Control, because this list con-
tains nearly all other DEGs. All significant DEGs of TP3
vs Control are shown in a heatmap in Figure 3B includ-
ing individual log2-fold-changes for all samples. It can
be seen that for the majority of DEGs, the level of regu-
lation is increasing proportionally with the RNA degra-
dation level.
Validation of the microarray data was performed by
qPCR using three representative candidates of under-
represented, over-represented and normally-represented
genes from the control group and TP3. Therefore, the
degradation experiment was repeated, i.e. RNA from the
same three patients was degraded again. To compare
the expression levels fold changes between the two time
points were assessed as illustrated in Figure 4 showing
similar patterns of over- and under-representation. Only
the normally-represented group showed a slight ten-
d e n c yt ob em o r ed e g r a d e di nt h eq P C Re x p e r i m e n t s
than in the microarray results. This might be explained
by a higher stability of the house-keeping genes that
were used in the qPCR experiments or by the fact that
qPCR reveals the general trend of degradation, also
observed on the microarray but removed due to the
normalization procedure. Generally the direction of
change remains consistent for the two groups of over-
represented and under-represented genes.
Interestingly, the relative differences in the qPCR are
smaller compared to the microarray data. This finding
might be explained by the different techniques of
reverse transcription that is carried out by random
priming for the qPCR and by oligo-dT for the microar-
ray experiments. Since random priming can occur at
any position within the RNA and is not restricted to the
3′ end subsequent PCR will be successful if the entire
amplicon is contained within a single cDNA molecule.
This is dependent on the size of the RNA fragments
present during RT and the size of the amplicon during
qPCR but the absolute position of the amplicon within
the RNA is not critical. This is different for microarray
experiments where cDNA synthesis is initiated at the 3′
end of the mRNA. As a result, qPCR may to be more
robust than DNA-chip analyzes.
To functionally characterize the genes affected by
RNA degradation, we searched for over-represented
Gene Ontology terms. The analysis to detect enriched
Gene Ontology (GO) terms was carried out separately
for under- and over-represented RNAs to identify
groups of genes with similar functions. The results of
significant GO terms (p-value < 0.01) are listed in
Table 3.
Although some significant GO terms exist, no relation
to known RNA degradation processes or to pathways
that are initiated during apoptosis could be found. The
absence of these findings clearly shows that changes of
the expression profile are generated at the RNA level
and not by de-novo transcription, as expected from the
experimental design.
A sc a nb es e e nb yt h i sa n a l y s i s ,w ed on o to b s e r v ea
global effect of RNA degradation on gene expression.
RNA degradation seems to have a significant influence
only on a fairly small number of genes. If such a global
effect of RNA degradation does indeed exist, we do not
observe it in the measured gene expression profiles.
Indeed it is possible that such an effect is removed by
Table 2 Summary of Gene Regulation
Comparison #Over-Represented #Under-Represented #Normally-Represented
TP1 vs Control 11 4 40985
TP2 vs Control 22 51 40937
TP3 vs Control 65 210 40725
All genes are grouped by the type of regulation for all comparisons. To filter differentially expressed genes we used the following thresholds: fdr <5% and fold
change greater 2 or less than 1/2.
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nature of the hybridization experiments, microarrays
produce only a relative measure of gene expression and
normalization between the experiments is therefore
essential to make the expression intensities comparable.
This fact is also necessary to explain the observed over-
represented probes (i.e. 65 out of 41,000). These are
likely to reflect genes that are relatively less severely
affected by RNA degradation than the majority of the
measured mRNAs. Therefore, on the other hand the
observed under-represented probes (i.e. 210 out of
41.000) reflect genes which are relatively more greatly
affected by RNA degradation than the mRNAs of most
other genes. This might mean that their mRNAs are less
stable. Therefore, in analyses comparing patient samples
with varying RNA quality, one should be careful with
the interpretation of results when observing these genes
as dysregulated.
Characterization of sequence features in differentially
expressed genes
The RNA degradation process is not entirely explained,
yet. On the one hand it is postulated, that the process
starts from the 5′ end [3,24,25], on the other hand a
more random mechanism including endonucleases
activity has to be expected. This becomes evident
interpreting the bioanalyzer data. If the mRNA would
be degraded only from one side a broader peak within
the 28 S and 18 S peak would be observable. For both
assumptions it could be hypothesized that probes which
are closer to the 3′ end should be efficiently hybridized
a n db em o r es t a b l et h a nt h o se located closer to the 5′
end. This is also accounted for by the fact that the Agi-
lent microarray probes are predominantly located near
the 3′ end of the mRNA but also due to the important
step of reverse transcription. In case of random degrada-
tion incomplete cDNA synthesis becomes more and
more probable by the increases of the distance between
3′ end (location of poly-A-tail that serves as starting
point) and the mRNA sequence that later serves as the
probe.
To analyze the effect of oligo positions on expression
measurements, we determined the relative positions of
Agilent’s 60 mer probes within the best matching tran-
scripts via Blast against all available NCBI RefSeq
Human transcripts.
The comparison of oligo positions between DEGs and
all other probes shows significant differences. The rela-
tive positions of probes from under-represented genes
are shifted to the 5′ region, while probes of normally-
represented genes are closer to the 3′ end, as can be seen
in Figure 5A. This observation is further underlined by
Figure 3 Differentially Expressed Genes.( A) shows a Venn diagram obtained from all comparisons. Numbers in the circles indicate the
amount of overlapping genes between lists of differentially expressed genes. The heatmap in (B) shows log2-fold changes for all significant
DEGs selected from comparison TP3 vs Control. Red colors indicate over-represented and blue colors under-represented genes in comparison to
the corresponding control samples.
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probe start. We observed that the distance to the 5′ end
of probes from under-represented genes is significantly
smaller than the distance of probes from normally-repre-
sented genes (see Figure 5B). Similarly probes in the
under-represented group are further away from the 3′
end, see Additional file 1, Fig u r eS 1 .T h i si sc o n s i s t e n t
with the comparison of the supposed mRNA lengths
between the different groups of genes. Here, we also
found significant differences between under-represented
and normally-represented genes. Figure 5C shows that
the mRNA-lengths of under-represented genes are signif-
icantly shorter (Bonferroni corrected p-value from two-
sample Wilcoxon test was <0.001). This might be due to
the degradation mechanisms that result in a higher prob-
ability of loss of detection. However, it does not mean
that short RNAs are degraded quicker or more prone to
degradation.
In contrast, the genes that appear to be more stable
are very long. We consider this over-representation to
be due to a more severe degradation of loss of the
remaining genes. This means the over-represented genes
a r ev e r ys t a b l eg e n e s ,e v e nm o r es t a b l et h a nt h en o r -
mally-represented group, i.e. seemingly not-differential
genes that in fact follow a general trend of degradation
and reduction of the RNA levels. This is however, not
relevant for differential gene expression as the gene
expression levels are normalized to the total amount of
RNA.
To validate the microarray results, qPCR was per-
formed using three representative candidates of the
over-represented, under-represented and normally-
represented genes. Although the fold change from qPCR
that was used to assess the difference between the two
time points was lower than that from microarray ana-
lyses, the direction of regulation could be confirmed for
the over- and under-represented genes. The result
seems to be conflicting for the normally-represented
genes. However, this difference can be attributed to the
different normalization procedures on the array, i.e.
based on the overall mean, or in the qPCR data, i.e.
based on housekeeping genes, as well as on the the dif-
ferent mechanisms of reverse transcription that is used
for qPCR and expression arrays. While the decrease of
signal intensity over the entire array between the two
time points is not visible within the normalized array
data they are apparent using qPCR. The nucleotide
composition is often used to determine stability or
instability of nucleic acids. The GC content especially is
an indicator of stability of secondary structures. The
Figure 4 Comparison of Microarray and qPCR results for candidate genes. Heatmaps from microarray (left side) and qPCR (right side).
Colors represent relative differences between TP3 vs. Control. 9 genes from 3 groups of representation (from top to bottom: over-represented,
under-representation and normally-represented in the microarray data) are shown.
Opitz et al. BMC Medical Genomics 2010, 3:36
http://www.biomedcentral.com/1755-8794/3/36
Page 9 of 14Table 3 Gene Ontology Analysis
Under-represented Genes
Ontology Rank GO.ID Term Annotated Significant Expected Rank in
classic
classic elim weight
BP 1 GO:0006099 tricarboxylic acid cycle 41 6 0.23 1 9.7e-08 9.7e-08 9.7e-08
2 GO:0045900 negative regulation of translational
elongation
6 3 0.03 10 3.3e-06 3.3e-06 3.3e-06
3 GO:0046500 S-adenosylmethionine metabolic
process
7 3 0.04 12 5.7e-06 5.7e-06 5.7e-06
4 GO:0006446 regulation of translational initiation 70 5 0.39 19 4.3e-05 4.3e-05 4.3e-05
5 GO:0006614 SRP-dependent cotranslational protein
targeting to membrane
13 3 0.07 20 4.5e-05 4.5e-05 4.5e-05
6 GO:0007021 tubulin complex assembly 5 2 0.03 31 0.00030 0.00030 0.00030
7 GO:0046498 S-adenosylhomocysteine metabolic
process
5 2 0.03 32 0.00030 0.00030 0.00030
8 GO:0030091 protein repair 6 2 0.03 33 0.00045 0.00045 0.00045
9 GO:0006425 glutaminyl-tRNA aminoacylation 1 1 0.01 51 0.00554 0.00554 0.00554
10 GO:0006430 lysyl-tRNA aminoacylation 1 1 0.01 52 0.00554 0.00554 0.00554
11 GO:0043393 regulation of protein binding 25 2 0.14 54 0.00839 0.00839 0.00839
MF 1 GO:0000104 succinate dehydrogenase activity 8 5 0.04 1 2.4e-10 2.4e-10 2.4e-10
2 GO:0005047 signal recognition particle binding 7 3 0.04 3 5.4e-06 5.4e-06 5.4e-06
3 GO:0045182 translation regulator activity 211 8 1.15 4 2.1e-05 0.27124 2.1e-05
4 GO:0008312 7 S RNA binding 14 3 0.08 5 5.5e-05 5.5e-05 5.5e-05
5 GO:0008119 thiopurine S-methyltransferase activity 3 2 0.02 7 8.8e-05 8.8e-05 8.8e-05
6 GO:0003924 GTPase activity 328 8 1.79 8 0.00044 0.00044 0.00044
7 GO:0004719 protein-L-isoaspartate (D-aspartate) O-
methyltransferase activity
10 2 0.05 16 0.00129 0.00129 0.00129
8 GO:0005525 GTP binding 592 10 3.22 19 0.00150 0.00150 0.00150
9 GO:0009055 electron carrier activity 349 7 1.90 22 0.00304 0.00304 0.00304
10 GO:0004819 glutamine-tRNA ligase activity 1 1 0.01 26 0.00544 0.00544 0.00544
11 GO:0004824 lysine-tRNA ligase activity 1 1 0.01 27 0.00544 0.00544 0.00544
12 GO:0003723 RNA binding 1269 17 6.91 10 0.00052 0.00680 0.00680
CC 1 GO:0005786 signal recognition particle, endoplasmic
reticulum targeting
15 4 0.08 3 1.2e-06 1.2e-06 1.2e-06
2 GO:0005785 signal recognition particle receptor
complex
7 3 0.04 5 6.0e-06 6.0e-06 6.0e-06
3 GO:0005853 eukaryotic translation elongation factor
1 complex
17 3 0.10 11 0.00011 0.00011 0.00011
4 GO:0002079 inner acrosomal membrane 4 2 0.02 13 0.00019 0.00019 0.00019
5 GO:0042589 zymogen granule membrane 5 2 0.03 16 0.00031 0.00031 0.00031
6 GO:0008290 F-actin capping protein complex 7 2 0.04 24 0.00065 0.00065 0.00065
7 GO:0005743 mitochondrial inner membrane 391 11 2.20 6 1.3e-05 1.3e-05 0.00263
8 GO:0044444 cytoplasmic part 6340 68 35.62 1 1.5e-09 0.01111 0.00499
9 GO:0045273 respiratory chain complex II 3 2 0.02 10 9.4e-05 9.4e-05 0.00558
10 GO:0005759 mitochondrial matrix 295 6 1.66 30 0.00652 0.00652 0.00652
Over-represented Genes
Ontology Rank GO.ID Term Annotated Significant Expected Rank in
classic
classic elim weight
BP 1 GO:0018279 protein amino acid N-linked
glycosylation via asparagine
20 2 0.02 1 0.00013 0.00013 0.00013
2 GO:0006414 translational elongation 253 3 0.22 3 0.00127 0.00127 0.00127
3 GO:0000722 telomere maintenance via
recombination
2 1 0.00 5 0.00173 0.00173 0.00173
4 GO:0009446 putrescine biosynthetic process 2 1 0.00 6 0.00173 0.00173 0.00173
5 GO:0051258 protein polymerization 106 2 0.09 8 0.00374 0.00374 0.00374
6 GO:0008295 spermidine biosynthetic process 6 1 0.01 9 0.00519 0.00519 0.00519
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Page 10 of 14results of comparisons according to the GC content are
given in Figure 5D. Under-represented genes have a sig-
nificantly lower GC content than the normally-repre-
sented genes.
In summary, we showed that different sequence features,
such as probe position, mRNA-length or GC content, play
a role in the perceived effects of RNA degradation when
using microarrays for gene expression profiling.
Discussion
Decoding the transcriptome is a major goal in the pro-
cess to gain a better understanding of the underlying
mechanisms of a disease and the potential for discover-
ing therapeutic targets. Using microarray technology,
high-throughput expression data for the whole genome
can be generated within a short period of time. This
gives us the unique possibility of screening a high num-
ber of patient samples for a massive number of features.
Nevertheless, working with clinical samples is challen-
ging. It is important in this kind of investigation to have
a high degree of standardized procedures (e.g. storage of
tissue or isolation of RNA), as a technical bias might
otherwise arise that would override the biological differ-
ences of the samples. Furthermore, tissue quality is a
serious concern as well as RNA quality. RNA degrada-
tion always takes place in the tissue that is removed and
stored for later processing. However, this process is not
only influenced by the time between removing the spe-
cimen and the removal of the tissue specimen, but
rather by the time between removal of the specimen
and the disruption of the blood supply that depends on
the type of tissue that is removed. The level of degrada-
tion can vary tremendously, which leads to the question
of how far degradation influences the results of gene
expression screens.
To assess this influence, we simulated RNA degrada-
tion in vitro by using heat treatment of patient samples.
We believe that this approach provides data that is
more relevant to our approach of gene expression profil-
ing. However, it remains unclear to which extent this
resembles the in-vitro situation or changes during tissue
preparation. Since in previous studies, tissue was treated
to achieve degradation [4-6]. Those studies have to deal
with the problem of differences due to functional
changes in living cells such as apoptotic changes for
example. We therefore used heat induced degradation
that has previously been used in [26].
Moreover, degradation of mRNA itself instead of
degradation of the tissue after removal is closer to the
clinical routine. Firstly because in the clinical practice of
taking rectal cancer biopsies, for example, the tissue is
taken from the patients and transferred into RNA con-
serving fluid within less than 20 seconds. Secondly,
when using the same mRNA for later analysis, the
homogeneity of the investigated material is higher than
when taking different tissue samples. For normal tissue,
the problem of heterogeneity might be negligible, but in
cancer, that is well known for its heterogeneous set-up,
applying different tissue samples introduces the risk that
the heterogeneity is behind the expression differences,
and not the degradation.
To standardize the degradation state of the samples,
we used the RNA integrity number (RIN). As expected,
the RIN decreased as the time of heat treatment
increased. The degradation showed a similar trend that
was highly correlated for all patient samples.
The main purpose of our analysis was to investigate to
which extent RNA degradation limits the comparability
of gene expression data derived from rectal cancer biop-
sies from different patients. Although quality thresholds
Table 3: Gene Ontology Analysis (Continued)
7 GO:0007094 mitotic cell cycle spindle assembly
checkpoint
8 1 0.01 11 0.00691 0.00691 0.00691
8 GO:0007018 microtubule-based movement 157 2 0.14 13 0.00802 0.00802 0.00802
9 GO:0015937 coenzyme A biosynthetic process 10 1 0.01 15 0.00863 0.00863 0.00863
MF 1 GO:0004579 dolichyl-diphosphooligosaccharide-
protein glycotransferase activity
19 2 0.02 1 0.00014 0.00014 0.00014
2 GO:0008783 agmatinase activity 2 1 0.00 3 0.00187 0.00187 0.00187
3 GO:0005198 structural molecule activity 1149 5 1.08 4 0.00359 0.13592 0.00359
4 GO:0004594 pantothenate kinase activity 7 1 0.01 6 0.00654 0.00654 0.00654
5 GO:0003720 telomerase activity 8 1 0.01 7 0.00747 0.00747 0.00747
CC 1 GO:0008250 oligosaccharyl transferase complex 20 2 0.02 1 0.00013 0.00013 0.00013
2 GO:0005840 ribosome 407 3 0.35 13 0.00493 0.00493 0.00493
The GO analysis was applied to differentially expressed genes from the comparison TP3 vs. Control. The number of genes belonging to a GO term represented
on the microarray (annotated), the number genes in the analyzed gene list (significant) and the expected number of genes by chance are given. The upper part
of the table shows GO terms that are highly significant for under-represented genes (p-value < 0.01); the lower part indicates terms that are highly significant for
over-represented genes. Calculated p-values for each category from three similar methods (classic, elim, weight) are shown. Each table is separated into three
different parts representing the following ontologies: Biological Process (BP), Molecular Function (MF) and Cellular Component (CC).
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Page 11 of 14of 6 or 7 were set in the past [4,5] these results have to
be interpreted carefully since non-cancerous tissue (e.g.
rat liver) or different conservation methods (fresh fro-
zen) were applied. Furthermore, as already discussed,
different biopsies from patients with rectal cancer pre-
viously degraded in a time-dependent manner were
analyzed.
I nap r e l i m i n a r yt e s t ,R N Aw a se x p o s e dt od i f f e r e n t
temperature levels. No degradation occurred at room
temperature and only very little at 45°C. Additionally,
very different levels of degradation were retrieved com-
p a r e dt ot h es e t u pa t6 0 ° C .T og e tc o m p a r a b l e
degradation results, we therefore choose four time
points that showed RIN differences of up to 4 levels
( P 1 5 9 ;0 : 0 0hR I N9a n d3 : 1 5hR I N4 . 7 ) .I n t e r e s t i n g l y ,
PCA as well as clustering analysis revealed very high
similarity of samples from the same patient and samples
from different patients did not cluster together revealing
their high biological divergence.
Although biology was the dominating effect of both
PCA and cluster analysis in our case, certain gene
expression differences were found and became more
and more evident the more the RNA was degraded.
Apart from an overlap of genes between the samples at
Figure 5 Characterization of sequence features. Comparison of sequence features for all genes from the following groups: normally-
represented, under-represented and over-represented or more stable genes in TP3 vs Control. The numbers on top indicate the significance
levels. The p-values were obtained using the two-sample Wilcoxon test and are Bonferroni corrected. The numbers at the bottom indicate the
quantity of genes belonging to the respective group. (A) compares the relative probe positions in the corresponding cDNA sequences. (B)
shows the absolute distance of the probe to the cDNA 5’ end. (C) displays the effect of absolute cDNA lengths. (D) shows the differences in GC
content between the explored groups.
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Page 12 of 14comparable degradation time points, genes that were
differentially expressed at an early degradation time
point reappeared as differentia l l ye x p r e s s e da tt h el a t e r
time points as well, indicating that changes observed on
gene expression in all three comparisons originated
exclusively from the degradation. Furthermore, the over-
or under-expression of a given gene was constant
throughout the entire experiment. Though these
changes were not derived from specific regulatory pro-
cesses we considered these changes not as an expression
itself but rather as a representation of the genes.
Since we considered these changes in dysregulation as
specific, we looked more closely at these genes trying to
find functional similarities. Using Gene Ontology, a few
processes were found but none of them could be put
into the context of degradation.
These results suggest that degradation activated by
heating is closely and more related with the nature of
mRNA degradation than with the activation of a path-
way involved in a specific biological process. We identi-
fied short mRNAs to be under-represented that might
be due to the higher probability of affecting sequences
that are important for detection by microarray.
A third stability marker for a more stable gene expres-
sion was the position of the complementary probe
which was spotted within the gene. Accordingly, genes
with probes that were designed to bind closer to the 3′
end were found to be more stable.
Investigating the length distribution and probe posi-
tions of the most under-represented genes, we found
that short genes especially were affected, as well as
t h o s ew i t has h o r td i s t a n c eb e t w e e nt h e5 ′ end and the
probe binding sequence.
This finding is based on two essential degradation
mechanisms. First the degradation from the 5′ end but
second and more obvious a random degradation. In that
case affection of the mRNA between the 3′ end (where
the Poly-A-tail is located and that is used for reverse
transcription in Agilent arrays) and the sequence that
later binds to the array probe is more probable the
longer the distance between the probe and the 3′ end,
or the shorter the distance between the probe and the 5′
end, respectively. In this context, we can also assume
that degradation by heating is less effective for longer
transcripts with a high GC content.
However, these results have some limitations. The
platform used within these analyses has to be taken into
consideration. Apart from different methods of reverse
transcription as for example the use of oligo-dT primers
versus random hexamers the platform itself might play a
major role. While the probes that are spotted on the
Agilent 44 K array used here are 60 mer long those
from the Affymetrix chip for example are only 25 bp
long. This difference might strongly influences the
binding characteristics to the microarray, especially
when degraded RNA is used. Furthermore we investi-
gated a small group of different rectal cancers. The
results, that implicit a much higher difference based on
biology than on degradation might only hold true as
long as such heterogeneity within the investigated sam-
ples can be found.
Conclusions
In summary, RNA degradation is an important process
that might hinder the analysis of gene expression pro-
files from patient samples. Patient samples are valuable
in clinical studies; therefore, we have to assess which
samples, with respect to RNA quality, can be used in
later analysis and which samples cannot be used. In
conclusion, RNA of different quality can be used to per-
form gene expression analysis due to a much higher bio-
logical variance, like in our case compared to the effect
that is imposed by degradation of RNA. Nevertheless
there are few genes that are detected with lower signals
on the microarray due to degradation, especially very
short ones and those with the probe binding site close
to the 5′ end. As a consequence of degradation, not only
are the short genes affected in their differential expres-
sion, but additionally the very long genes appear differ-
ent due to the fact that they are less affected by
degradation. Therefore, these genes should be excluded
from gene expression analysis when working with
degraded RNA.
Additional material
Additional file 1: Supplementary Figure S1. The absolute distance of
the probe to the cDNA 3’ end for all genes from the following groups is
shown: normally-represented, under-represented and over-represented
genes in TP3 vs Control. The numbers on top indicate the significance
levels. The p-values were obtained using the two-sample Wilcoxon test
and are Bonferroni corrected. The numbers at the bottom indicate the
quantity of genes belonging to the respective group.
Additional file 2: Supplementary Figure S2. We checked the technical
reproducibility of Agilent microarray results using the 3 patient samples
analyzed here. We investigated the robustness of gene expression
profiles in dependence of: 1. the experimenter (E); or 2. repeating the
labelling (L); or 3. repeating the hybridization (H); or 4. using different
washing methods (W). These types of technical replicates where highly
correlated and clustered together. Supplementary Figure 2 shows
pairwise correlations between all samples of patients. The elements of
the matrix in the visualization are colored by Pearson’s correlation
coefficient values with deeper colors indicating higher positive (blue)
correlations. The heatmap is flanked by clustering dendrograms showing
the similarity between samples in a hierarchical approach.
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